Evidence map›Paper›PMID 33559012›Full record

ReviewDer Urologe. Ausg. A2021

[COVID-19 in european urology : Which lessons have we learned?]

J J Rassweiler, G Pini, F Liatsikos, M Georgiev, M Roupret, A Breda, T Knoll, S Micali, A Stenzl, A S Goezen and 2 more

Abstract readReview
In one paragraph

Review in Der Urologe. Ausg. A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

J J RassweilerKlinik für Urologie und Kinderurologie SLK Kliniken Heilbronn, Akademisches Lehrkrankenhaus der Universität Heidelberg, Heidelberg, Deutschland. jens.rassweiler@slk-kliniken.de.
G PiniIRCSS San Raffaele Hospital, 20132, Mailand, Lombardei, Italien.
F LiatsikosDepartment of Urology, University of Patras, Patras, Griechenland.
M GeorgievDepartment of Urology, Medical University Sofia, Sofia, Bulgarien.
M RoupretGRC 5 Predictive ONCO-URO, AP-HP, Urology, Pitié-Salpetrière Hospital, Sorbonne University, Paris, Frankreich.
A BredaDepartment of Uro-oncology and Transplantation, Fundacio Puigvert, Barcelona, Spanien.
T KnollUrologische Klinik, Klinikum Sindelfingen-Böblingen, Klinikverbund-Südwest, Sindelfingen-Böblingen, Deutschland.
S MicaliDepartment of Urology, University of Modena and Reggio Emilia, Modena, Italien.
A StenzlUrologische Universitätsklinik Tübingen, Tübingen, Deutschland.
A S GoezenKlinik für Urologie und Kinderurologie SLK Kliniken Heilbronn, Akademisches Lehrkrankenhaus der Universität Heidelberg, Heidelberg, Deutschland.
K YanevDepartment of Urology, Medical University Sofia, Sofia, Bulgarien.
M-C Rassweiler-SeyfriedKlinik für Urologie und Urochirurgie, Universitätsmedizin Mannheim, Mannheim, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus has challenged all medical systems worldwide. Herein both waves of COVID-19 (coronavirus disease 2019) in spring and autumn 2020 differ principally. Whereas Europe was hit by the first wave more or less unprepared, which was aggravated by the high virulence of COVID-19, the second wave is characterized by a much higher contagiosity of the virus with very high incidences. On the other hand the virus has attenuated, which is reflected by the significantly lower incidence-related mortality rate. However, the overall increasing number of infected patients represents again a great challenge for the medical management of the disease. France and Spain are doing better in comparison to Germany and Italy this time. The absolute number of deaths per week is higher than during the peak of the first wave. However, urologists in these countries have also experienced greater restrictions in their activities in the second shutdown than in Germany, where there is only a reduction of beds to between 75 and 90%. Mostly all levels are operated. Of importance for Germany, however, is the plateau on a high level for several weeks probably due to the reduced efficacy of a light lock-down. This finally resulted in a total lock-down in mid-December 2020. Subsequently in Germany some hospitals are also reaching their limits with similar consequences for the departments of urology facing a 50% reduction of beds and operating only level III and IV indications. Nevertheless, the management of urologic patients during the COVID-19 pandemic is carried out in Europa on a high standard. Therefor the risk of secondary harm to our patients is expected to be rather minimal in the long run.

Indexed as

COVID-19UrologyCommunicable Disease ControlEuropeFranceGermanyHumansItalyPandemicsSARS-CoV-2Capacities of intensive careCoronavirusIncidenceMortalityPandemic

Identifiers

PMID33559012
PMCPMC7869769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.